- Home
- NBH vs PGEN Comparison
NBH vs PGEN Comparison
Compare NBH & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- PGEN
- Stock Information
- Founded
- NBH 2002
- PGEN 1998
- Country
- NBH United States
- PGEN United States
- Employees
- NBH N/A
- PGEN N/A
- Industry
- NBH Finance/Investors Services
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NBH Finance
- PGEN Health Care
- Exchange
- NBH Nasdaq
- PGEN Nasdaq
- Market Cap
- NBH 291.1M
- PGEN 344.0M
- IPO Year
- NBH N/A
- PGEN N/A
- Fundamental
- Price
- NBH $9.85
- PGEN $1.39
- Analyst Decision
- NBH
- PGEN Strong Buy
- Analyst Count
- NBH 0
- PGEN 4
- Target Price
- NBH N/A
- PGEN $7.33
- AVG Volume (30 Days)
- NBH 85.9K
- PGEN 1.5M
- Earning Date
- NBH 01-01-0001
- PGEN 05-13-2025
- Dividend Yield
- NBH 4.34%
- PGEN N/A
- EPS Growth
- NBH N/A
- PGEN N/A
- EPS
- NBH 0.12
- PGEN N/A
- Revenue
- NBH N/A
- PGEN $3,925,000.00
- Revenue This Year
- NBH N/A
- PGEN $318.39
- Revenue Next Year
- NBH N/A
- PGEN $789.17
- P/E Ratio
- NBH $87.04
- PGEN N/A
- Revenue Growth
- NBH N/A
- PGEN N/A
- 52 Week Low
- NBH $8.75
- PGEN $0.65
- 52 Week High
- NBH $11.01
- PGEN $2.17
- Technical
- Relative Strength Index (RSI)
- NBH 35.83
- PGEN 44.92
- Support Level
- NBH $9.80
- PGEN $1.12
- Resistance Level
- NBH $9.98
- PGEN $1.49
- Average True Range (ATR)
- NBH 0.19
- PGEN 0.14
- MACD
- NBH -0.03
- PGEN 0.00
- Stochastic Oscillator
- NBH 36.19
- PGEN 63.64
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.